Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7MW3711 + JS207 in advanced solid tumors (Ib/II, China)
CTR20260318Phase 2Active
- Sponsor
- Maiwei Biotech
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 7MW3711, JS207 in Non-hematologic malignancy, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by Maiwei Biotech. Started Feb 2026; status: active.
02
Drugs
7MW3711JS207
03
Conditions
Non-hematologic malignancynon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20260318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260318.